273 related articles for article (PubMed ID: 29696665)
21. Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B.
Kim YM; Shin HP; Lee JI; Joo KR; Cha JM; Jeon JW; Yoon JY; Kwak MS
Saudi J Gastroenterol; 2018; 24(6):326-335. PubMed ID: 30004042
[TBL] [Abstract][Full Text] [Related]
22. Tenofovir Versus Entecavir for the Treatment of Acute-on-Chronic Liver Failure due to Reactivation of Chronic Hepatitis B With Genotypes B and C.
Wan YM; Li YH; Xu ZY; Wu HM; Xu Y; Wu XN; Yang JH
J Clin Gastroenterol; 2019 Apr; 53(4):e171-e177. PubMed ID: 29659382
[TBL] [Abstract][Full Text] [Related]
23. Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan.
Hu TH; Yueh-Hsia Chiu S; Tseng PL; Chen CH; Lu SN; Wang JH; Hung CH; Kee KM; Lin MT; Chang KC; Lin MC; Chien RN
Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1695-1706. PubMed ID: 33111400
[TBL] [Abstract][Full Text] [Related]
24. Entecavir and tenofovir on renal function in patients with hepatitis B virus-related hepatocellular carcinoma.
Jeon MY; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Han KH; Ahn SH; Kim SU
J Viral Hepat; 2020 Sep; 27(9):932-940. PubMed ID: 32365240
[TBL] [Abstract][Full Text] [Related]
25. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis.
Choi WM; Yip TC; Wong GL; Kim WR; Yee LJ; Brooks-Rooney C; Curteis T; Cant H; Chen CH; Chen CY; Huang YH; Jin YJ; Jun DW; Kim JW; Park NH; Peng CY; Shin HP; Shin JW; Yang YH; Lim YS
J Hepatol; 2023 Mar; 78(3):534-542. PubMed ID: 36572349
[TBL] [Abstract][Full Text] [Related]
26. Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience.
Tsai MC; Chen CH; Tseng PL; Hung CH; Chiu KW; Wang JH; Lu SN; Lee CM; Chang KC; Yen YH; Lin MT; Chou YP; Hu TH
Clin Microbiol Infect; 2016 Jan; 22(1):95.e1-95.e7. PubMed ID: 26055419
[TBL] [Abstract][Full Text] [Related]
27. The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis.
Han Y; Zeng A; Liao H; Liu Y; Chen Y; Ding H
Int Immunopharmacol; 2017 Jan; 42():168-175. PubMed ID: 27915131
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir.
Kuo MT; Hu TH; Hung CH; Wang JH; Lu SN; Tsai KL; Chen CH
Aliment Pharmacol Ther; 2019 Jan; 49(2):218-228. PubMed ID: 30484881
[TBL] [Abstract][Full Text] [Related]
29. Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate.
Ha Y; Chon YE; Kim MN; Lee JH; Hwang SG
Sci Rep; 2020 Aug; 10(1):13537. PubMed ID: 32782369
[TBL] [Abstract][Full Text] [Related]
30. Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
Jeong S; Shin HP; Kim HI
Intervirology; 2022; 65(2):94-103. PubMed ID: 34731856
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the Efficacy of Tenofovir Versus Tenofovir plus Entecavir in the Treatment of Chronic Hepatitis B in Patients With Poor Efficacy of Entecavir: A Systematic Review and Meta-analysis.
Chen J; Zhao SS; Liu XX; Huang ZB; Huang Y
Clin Ther; 2017 Sep; 39(9):1870-1880. PubMed ID: 28797777
[TBL] [Abstract][Full Text] [Related]
32. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review.
Tseng CH; Tseng CM; Wu JL; Hsu YC; El-Serag HB
J Gastroenterol Hepatol; 2020 Oct; 35(10):1684-1693. PubMed ID: 32343431
[TBL] [Abstract][Full Text] [Related]
33. Tenofovir is Associated With Higher Risk of Kidney Function Decline Than Entecavir in Patients With Chronic Hepatitis B.
Jung CY; Kim HW; Ahn SH; Kim SU; Kim BS
Clin Gastroenterol Hepatol; 2022 Apr; 20(4):956-958.e2. PubMed ID: 34029751
[TBL] [Abstract][Full Text] [Related]
34. Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis.
Yuan BH; Li RH; Huo RR; Li MJ; Papatheodoridis G; Zhong JH
J Gastroenterol Hepatol; 2022 May; 37(5):782-794. PubMed ID: 35080052
[TBL] [Abstract][Full Text] [Related]
35. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].
Shi H; Li XY; Zhu JY; Lin CS; Zhang Y
Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198
[No Abstract] [Full Text] [Related]
36. Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis.
Park J; Jung KS; Lee HW; Kim BK; Kim SU; Kim DY; Ahn SH; Han KH; Park JY
Gut Liver; 2017 Nov; 11(6):828-834. PubMed ID: 28651305
[TBL] [Abstract][Full Text] [Related]
37. Tenofovir monotherapy after achieving complete viral suppression on entecavir plus tenofovir combination therapy.
Kim LH; Chaung KT; Ha NB; Kin KC; Vu VD; Trinh HN; Nguyen HA; Nguyen MH
Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):871-6. PubMed ID: 25919771
[TBL] [Abstract][Full Text] [Related]
38. Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B.
Wei MT; Le AK; Chang MS; Hsu H; Nguyen P; Zhang JQ; Wong C; Wong C; Cheung R; Nguyen MH
J Med Virol; 2019 Jul; 91(7):1288-1294. PubMed ID: 30776311
[TBL] [Abstract][Full Text] [Related]
39. Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation.
Hung CH; Hu TH; Lu SN; Lee CM; Chen CH; Kee KM; Wang JH; Tsai MC; Kuo YH; Chang KC; Chiu YC; Chen CH
Antimicrob Agents Chemother; 2015; 59(6):3168-73. PubMed ID: 25779569
[TBL] [Abstract][Full Text] [Related]
40. Tenofovir-based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir.
Lu L; Yip B; Trinh H; Pan CQ; Han SH; Wong CC; Li J; Chan S; Krishnan G; Wong CC; Nguyen MH
J Viral Hepat; 2015 Aug; 22(8):675-81. PubMed ID: 25417914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
